Severe acute respiratory syndrome–related coronavirus

Ethris Announces Collaboration with DIOSynVax and CEPI to Develop a Broadly Protective mRNA Vaccine Against Betacoronaviruses

Retrieved on: 
Wednesday, December 21, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, LNP, Partnership, Coronavirus, SARS, Biotechnology, RNA transfection, Coalition for Epidemic Preparedness Innovations, Epidemic, COVID-19, Temperature, MERS, Disease, CEPI, Therapy, Severe acute respiratory syndrome–related coronavirus, Coalition, Vaccine, RNA, Severe acute respiratory syndrome coronavirus 2, Betacoronavirus, Nobecovirus

Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.

Key Points: 
  • Ethris GmbH , a leading biotechnology company pioneering next-generation messenger RNA (mRNA) therapeutics and vaccines, announced today a collaboration with UK-based DIOSynVax to jointly develop a protective mRNA vaccine candidate against a broad range of Betacoronaviruses utilizing the company’s highly differentiated mRNA modification and design technologies as well as its lipidoid nanoparticle (LNP) and stabilisation platforms.
  • The collaboration is founded on a $42 million award to DIOSynVax by the Coalition for Epidemic Preparedness Innovations (CEPI) to support the development of a broadly protective Betacoronavirus vaccine through to a Phase I/II clinical trial.
  • Ethris will receive up to $20M to design and manufacture the mRNA vaccine candidate containing DIOSynVax’s broadly protective, multi-virus vaccine antigen payload designs.
  • The company has established its proprietary platforms to design and manufacture next-generation, well-tolerated, mRNA drug candidates with unparalleled LNP stability.

Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19

Retrieved on: 
Tuesday, October 11, 2022
COCP, Therapy, Norovirus, SEC, Orthornavirae, IND, Cocrystal, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Nobel Prize, Kidney failure, Annual report, Patient, RNA, Research, Program, Federal Reserve, Enzyme, Nasdaq, Private Securities Litigation Reform Act, Company, Degenerative disease, Severe acute respiratory syndrome–related coronavirus, Intention, GLOBE, SARS, Protease, Death, COVID-19, Risk, Toxicology, Pharmaceutical industry

BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an oral treatment for SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • BOTHELL, Wash., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the selection of its novel, broad-spectrum antiviral drug candidate CDI-988 for clinical development as an oral treatment for SARS-CoV-2, the virus that causes COVID-19.
  • In January 2022 the Company announced its intention to evaluate two oral protease inhibitors prior to selecting a lead candidate for clinical development.
  • In preclinical studies, both candidates demonstrated favorable safety profiles and pharmacokinetic properties supportive of oral administration for the treatment of COVID-19.
  • We are very excited about the selection of the first oral clinical candidate among our proprietary protease inhibitors.

Deswell Announces Second Half 2022 Results

Retrieved on: 
Thursday, June 16, 2022
Engineering, Chemicals, Plastics, Machine Tools, Metalworking & Metallurgy, Manufacturing, Industry, Security (finance), Website, Severe acute respiratory syndrome–related coronavirus, Electronics, Company, U.S. Securities and Exchange Commission, IOT, COVID-19, Growth, Investment, Travel, Natural borrowing limit, Renminbi, Nasdaq, Plastic, Income, Sale, Online gambling, Life insurance, Bank

Deswell Industries, Inc. (Nasdaq: DSWL) today announced its unaudited financial results for the second half of the fiscal year ended March 31, 2022.

Key Points: 
  • Deswell Industries, Inc. (Nasdaq: DSWL) today announced its unaudited financial results for the second half of the fiscal year ended March 31, 2022.
  • For the electronic segment, gross profit margin decreased from 17.9% in the second half of fiscal 2021 to 15.4% in the second half of fiscal 2022.
  • Operating income for the second half of fiscal 2022 decreased from $2.3 million in the second half of fiscal 2021 to $1.7 million in the second half of fiscal 2022.
  • Deswell undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in Deswells expectations.

Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

Retrieved on: 
Wednesday, June 1, 2022
Severe acute respiratory syndrome–related coronavirus, NIAID, Research, Annual report, Gastroenteritis, National Institute of Allergy and Infectious Diseases, Federal Reserve, API, NIH, Nasdaq, Norovirus, Infection, Coronavirus diseases, National, Cocrystal, Patient, GLOBE, Private Securities Litigation Reform Act, COCP, COVID-19, NCEA, Risk, Nobel Prize, Protease, SARS, SEC, Severe acute respiratory syndrome coronavirus 2, National Institute, Enzyme, MERS, Protein, Pharmaceutical industry, Vaccine

BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to evaluate the potential of Cocrystals 3CL protease inhibitors for the treatment of COVID-19.

Key Points: 
  • BOTHELL, Wash., June 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID) for exploratory preclinical studies to evaluate the potential of Cocrystals 3CL protease inhibitors for the treatment of COVID-19.
  • Under the NIAID collaboration, Cocrystal has provided its proprietary process chemistry information for its oral 3CL protease inhibitors and the NIAID will support a scale-up synthesis of a key intermediate of the oral 3CL protease inhibitors.
  • We are grateful to receive the NIAID's additional support and look forward to further expanding our collaborative work going forward.
  • A division of the National Institutes of Health (NIH), NIAID conducts and supports basic and applied research to better understand, treat and ultimately prevent infectious, immunologic and allergic diseases.

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

Retrieved on: 
Wednesday, May 11, 2022
Nobel Prize, Chemistry, Merck, Safety, World Health Organization, CFO, United, Contract, Gastroenteritis, Animal, Annual report, Degenerative disease, SEC, Technology, Severe acute respiratory syndrome–related coronavirus, Protease, Company, Risk, Clinical trial, FDA, CRO, Government, Contract research organization, Disease, Liver, Research, Cocrystal, Botswana, Private Securities Litigation Reform Act, Insurance, IND, MERS, Pharmacokinetics, HCV, Enzyme, R, Severe acute respiratory syndrome coronavirus 2, Vaccine, Cros, Goal, Protein, SARS, COVID-19, Influenza, Coronavirus diseases, Nasdaq, GLOBE, COCP, Federal Reserve, Software, Trial of the century, Coronavirus, Online gambling, Pharmaceutical industry, Alpha, Sofosbuvir/velpatasvir, Norovirus

BOTHELL, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the three months ended March 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

Key Points: 
  • BOTHELL, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the three months ended March 31, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
  • Scale-up synthesis and process chemistry development are ongoing as we prepare data to support an IND application, Dr. Lee added.
  • By targeting these highly conserved regions of the replication enzymes, our antiviral compounds are designed and tested to be effective against major virus strains.
  • We selected investigational novel antiviral drug candidates CDI-988 and CDI-873 for further development as potential oral treatments for SARS-CoV-2.

Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

Retrieved on: 
Thursday, April 21, 2022
Protein, NCEA, Gastroenteritis, National Institute of Allergy and Infectious Diseases, MERS, NIH, Severe acute respiratory syndrome–related coronavirus, COVID-19, SARS, Risk, Research, Annual report, Enzyme, Private Securities Litigation Reform Act, GLOBE, National, Norovirus, Protease, Patient, Nobel Prize, Coronavirus diseases, Infection, NIAID, Technology, Nasdaq, SEC, Cocrystal, National Institute, COCP, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Vaccine

Cocrystal applied its proprietary drug discovery platform technology to develop novel, broad-spectrum SARS-CoV-2 3CL protease inhibitors.

Key Points: 
  • Cocrystal applied its proprietary drug discovery platform technology to develop novel, broad-spectrum SARS-CoV-2 3CL protease inhibitors.
  • We are pleased to collaborate with NIAID to further evaluate Cocrystals SARS-CoV-2 3CL protease inhibitors.
  • We are pleased that the NIAID has researched our novel, broad-spectrum protease inhibitors and has determined that further evaluation in an animal model is warranted.
  • Studies to date show that our protease inhibitors exhibit superior in vitro potency against SARS-CoV-2 and variants of concern including Omicron.

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Retrieved on: 
Wednesday, March 23, 2022
Private Securities Litigation Reform Act, Degenerative disease, COCP, Vaccine, Liver, Severe acute respiratory syndrome–related coronavirus, SEC, Research, Gastroenteritis, CEO, Software, Nobel Prize, Technology, Contract, Goal, Cocrystal, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Enzyme, ATM, Annual report, Botswana, Sale, Trial of the century, Risk, CMOS, Cros, Contract research organization, Animal, HCV, World Health Organization, Coronavirus, MERS, Coronavirus diseases, CFO, Severe acute respiratory syndrome coronavirus 2, Government, FDA, Protein, Merck, Company, SARS, Influenza, Food, United, Safety, COVID-19, CRO, Infection, R, Protease, Pharmaceutical industry, Sofosbuvir/velpatasvir, Norovirus, Alpha

We continue advancing multiple high-value antiviral compounds into clinical development and remain opportunistic, said James Martin, co-interim CEO and CFO.

Key Points: 
  • We continue advancing multiple high-value antiviral compounds into clinical development and remain opportunistic, said James Martin, co-interim CEO and CFO.
  • We selected investigational novel antiviral drug candidates CDI-988 and CDI-873 for further development as potential oral treatments for COVID-19.
  • We believe the FDAs guidance for further development of CDI-45205 provides us with a clearer pathway for the clinical development of our oral COVID-19 program.
  • Throughout 2020 Cocrystal reported revenues under an influenza A/B collaboration with Merck consisting of research and development (R&D) services performed by Cocrystal and reimbursed by Merck.

Deswell Announces First Half 2022 Results

Retrieved on: 
Monday, November 22, 2021
Chemicals, Plastics, Technology, Manufacturing, Other Technology, Audio, Video, Other Manufacturing, Hardware, Website, Security (finance), Computer Peripherals, SMT, Income, Company, Plastic, Severe acute respiratory syndrome–related coronavirus, U.S. Securities and Exchange Commission, Industry, Nasdaq, Natural borrowing limit, Travel, Growth

Deswell Industries, Inc. (Nasdaq: DSWL) today announced its unaudited financial results for the first six months of fiscal 2022, ended September 30, 2021.

Key Points: 
  • Deswell Industries, Inc. (Nasdaq: DSWL) today announced its unaudited financial results for the first six months of fiscal 2022, ended September 30, 2021.
  • Gross profit margin in the plastic segment decreased to 10.7% of net sales for the first half of fiscal 2022, compared to 20.4% of net sales for the corresponding period of last fiscal year.
  • Operating income in the first half of fiscal 2022 was $1.2 million, compared to operating income of $1.0 million for the same period of fiscal 2021.
  • Deswell undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in Deswells expectations.

Chasing the Cells that Predict Death from Severe COVID-19

Retrieved on: 
Thursday, July 1, 2021
Branches of biology, Medical specialties, Biology, Immune system, Immunology, Cell biology, T cell, T helper cell, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome–related coronavirus, La Jolla Institute for Immunology

By studying a type of immune cells called T cells, a team of Gladstone scientists has uncovered fundamental differences between patients who overcome severe COVID-19 and those who succumb to it.

Key Points: 
  • By studying a type of immune cells called T cells, a team of Gladstone scientists has uncovered fundamental differences between patients who overcome severe COVID-19 and those who succumb to it.
  • Our study suggests that it may also be beneficial to directly prevent excess immune cells, including inflammatory T cells, from entering the lung and causing further damage.
  • The scientists call these lung-homing cells "bystander T cells," because they are T cells that do not directly recognize the SARS-CoV-2 virus.
  • The paper "Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19" was published in Cell Reports on June 28.

NEC Contributes to Development of Artificial DNA Aptamer that Binds to the Novel Coronavirus (SARS-CoV-2)

Retrieved on: 
Thursday, May 6, 2021
Sarbecovirus, Zoonoses, Animal diseases, Bat virome, Veterinary medicine, Biotechnology, Nucleic acids, Aptamer, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome–related coronavirus, Coronavirus, Middle East respiratory syndrome–related coronavirus

b'TOKYO, May 6, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NEC Solution Innovators today announced the successful development of artificial DNA aptamers (1) that bind to the novel coronavirus (SARS-CoV-2).

Key Points: 
  • b'TOKYO, May 6, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NEC Solution Innovators today announced the successful development of artificial DNA aptamers (1) that bind to the novel coronavirus (SARS-CoV-2).
  • This aptamer uses a new modified base called Base appended Base ((5), Patent No.
  • In fiscal 2021, NEC expects to provide a prototype of a fixed-type spatial monitoring measuring device for companies, universities and other research institutions that perform virus measurement and other measures.
  • For more information, visit NEC at https://www.nec.com.\n'